Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue

Urology

Volumn 55, Issue 1, 2000, Pages 146-150

  Stief, Christian G ^a   Ückert, Stefan ^a   Becker, Armin J ^a   Harringer, Wolfgang ^a   Truss, Michael C ^a   Forssmann, Wolf Georg ^b   Jonas, Udo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b IPF PHARMACEUTICALS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; FORSKOLIN; MILRINONE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL;

ARTICLE; CARDIOVASCULAR EFFECT; CORPUS CAVERNOSUM; HEART MUSCLE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CYCLIC AMP; CYCLIC GMP; FORSKOLIN; HEART; HUMANS; MALE; MILRINONE; MYOCARDIUM; PENIS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES;

EID: 0033958337     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00371-4     Document Type: Article

References (22)

1. Boolell M., Allen M.J., Ballard S., et al. Sildenafil an orally active type 5 cGMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction . Int J Impot Res. 8:1996;47-52.
2. Goldstein I., Lue T.F., Padma-Nathan H., et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338:1998;1397-1404.
3. Feenstra J., van Drie-Pierik R.J., Lacle C.F., et al. Acute myocardial infarction associated with sildenafil. Lancet. 352:1998;957-958.
4. Braunwald E. Intravenous milrinone therapeutic responses in heart failure . Am Heart J. 121:1991;1937-1938.
5. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 325:1991;1468-1475.
6. Mulhall J.P., Daller M., Traish A.M., et al. Intracavernosal forskolin role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy . J Urol. 158:1997;1752-1759.
7. Miller M.A., Morgan R.J., Thompson C.S., et al. Effects of papaverine and vasointestinal polypeptide on penile and vascular cAMP and cGMP in control and diabetic animals an in vitro study . Int J Impot Res. 7:1995;91-100.
8. Ellis P, and Terrett KN: Pyrazolopyrimidinones for the treatment of impotence. International application published under the patent cooperation treaty (PCT). Application No. PCT/EP94/01580, June 9, 1993.
9. Küthe A., Stief C.G., Mägert H.J., et al. Molecular biological characterization of phosphodiesterases 3A and 5 in human corpus cavernosum penis. Eur Urol. 35:(suppl 2):1999;102.
10. Taher A., Meyer M., Schulz-Knappe P., et al. Phosphodiesterase activity in human cavernous tissue and the effect of various selective inhibitors. J Urol. 149:1993;285A.
11. Stief C.G., Ückert S., Truss M.C., et al. Cyclic nucleotide phosphodiesterase isoenzymes in human cavernous smooth muscle characterization and functional effects of various PDE-inhibitors in vitro and in vivo . Int J Impot Res. 7:(suppl 1):1996;6.
12. Küthe A., Wiedenroth A., Stief C.G., et al. Identification of 13 phosphodiesterase isoforms in human cavernous tissue. Eur Urol. 35:(suppl 2):1999;101.
13. 2+/calmodulin-dependent forms of cyclic nucleotide phosphodiesterase by using conformation specific monoclonal antibody chromatography. Proc Natl Acad Sci USA. 79:1984;2788-2792.
14. Weishaar R.E., Kobylarz-Singer D.C., Steffen N.P., et al. Subclasses of cyclic cAMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating cardiac contractility. Circ Res. 61:1987;539-547.
15. Wallis R.M., Corbin J.D., Francis S.H., et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 83:(suppl 5A):1999;3C-12C.
16. Bristol J.A., Sircar I., Moos W.H., et al. 4.5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones novel positive inotropic agents for the treatment of congestive heart failure . J Med Chem. 27:1984;1099-1101.
17. Maurice D.H., Haslam R.J. Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Eur J Pharmacol. 191:1990;471-475.
18. Jeremy J.Y., Ballard S.A., Naylor A.M., et al. Effects of sildenafil, a type 5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum. Br J Urol. 79:1997;958-963.
19. Chuang A.T., Strauss J.D., Murphy R.A., et al. Sildenafil, a type 5 cGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J Urol. 160:1998;257-261.
20. Nicholson C.D., Chaliss R.A., Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci. 12:1991;19-21.
21. Shah P.K. Sildenafil in the treatment of erectile dysfunction. N Engl J Med. 10:1998;699. (letter).
22. Nelson R.P., Barada J.H., Costabile R.A., et al. Does renewed sexual activity increase cardiac morbidity? Meta-analysis of the experience with MUSE™ J Urol. 161:1999;215.